Market Overview on Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2016

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Head And Neck Cancer Squamous Cell Carcinoma (Oncology) pipeline landscape.

Head and Neck Cancer Squamous Cell Carcinoma is a cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx. The common symptoms of cancer of the head and neck include persistent pain in the throat, pain or difficulty with swallowing, persistent hoarseness or a change in voice, pain in the ear and bleeding in the mouth or throat. The disease may be controlled by chemotherapy and radiation therapy.

Report Highlights

This report provides comprehensive information on the therapeutics under development for Head And Neck Cancer Squamous Cell Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Complete report available @ Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2016

The Head And Neck Cancer Squamous Cell Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 14, 49, 49, 2, 23, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 4 and 2 molecules, respectively.Head And Neck Cancer Squamous Cell Carcinoma.

Head And Neck Cancer Squamous Cell Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Head And Neck Cancer Squamous Cell Carcinoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Head And Neck Cancer Squamous Cell Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Head And Neck Cancer Squamous Cell Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Head And Neck Cancer Squamous Cell Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Head And Neck Cancer Squamous Cell Carcinoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Head And Neck Cancer Squamous Cell Carcinoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Head And Neck Cancer Squamous Cell Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

AB Science SA AbbVie Inc Accelerated Pharma, Inc. Acceleron Pharma, Inc. Adaptimmune Therapeutics Plc Advaxis, Inc. Altor BioScience Corporation Amgen Inc. AstraZeneca Plc AVEO Pharmaceuticals, Inc. Bayer AG Bionovis SA BioNTech AG Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Calithera Biosciences, Inc. CEL-SCI Corporation Cellceutix Corporation Celldex Therapeutics, Inc. Centrose LLC Critical Outcome Technologies Inc. CytImmune Sciences, Inc. Daiichi Sankyo Company, Limited Eisai Co., Ltd. Eleven Biotherapeutics Inc. Eli Lilly and Company Etubics Corporation F. Hoffmann-La Roche Ltd. G&E Herbal Biotechnology Co., Ltd. GeneSegues Inc Genexine, Inc. Genmab A/S GlaxoSmithKline Plc Gliknik, Inc. Glycotope GmbH Hanmi Pharmaceuticals, Co. Ltd. Horizon Pharma Plc Immunomedics, Inc. Immunovative Therapies, Ltd. Incyte Corporation Infinity Pharmaceuticals, Inc. Innate Pharma S.A. Inovio Pharmaceuticals, Inc. IRX Therapeutics, Inc. Johnson & Johnson Kolltan Pharmaceuticals, Inc. Laboratoires Pierre Fabre SA Loxo Oncology, Inc. Mabion SA MacroGenics, Inc. Marsala Biotech Inc. Mateon Therapeutics Inc MedImmune LLC Merck & Co., Inc. Merck KGaA Merrimack Pharmaceuticals, Inc. Millennium Pharmaceuticals Inc Mirati Therapeutics Inc. Molecular Partners AG Molplex Ltd. NanoCarrier Co., Ltd. Novartis AG Oncobiologics, Inc. Oncolytics Biotech Inc. Onconova Therapeutics, Inc. OncoSec Medical Incorporated Ono Pharmaceutical Co., Ltd. Panacea Biotec Limited PCI Biotech Holding ASA Pfizer Inc. Reliance Life Sciences Pvt. Ltd. Sanofi Shanghai Henlius Biotech Co., Ltd. Shionogi & Co., Ltd. Sillajen Biotherapeutics Symphogen A/S SynCore Biotechnology Co., Ltd. Takara Bio Inc. Tara Immuno-Oncology Therapeutics LLC Transgene SA UbiVac, LLC VasGene Therapeutics, Inc. VentiRx Pharmaceuticals, Inc. Virttu Biologics Limited Vyriad Inc

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

ReportstackMarket Research

###